These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27423481)

  • 1. Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.
    Dwyer MP; Keertikar KM; Chen L; Tong L; Selyutin O; Nair AG; Yu W; Zhou G; Lavey BJ; Yang DY; Wong M; Kim SH; Coburn CA; Rosenblum SB; Zeng Q; Jiang Y; Shankar BB; Rizvi R; Nomeir AA; Liu R; Agrawal S; Xia E; Kong R; Zhai Y; Ingravallo P; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4106-11. PubMed ID: 27423481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
    Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW
    ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors.
    Tong L; Yu W; Coburn CA; Chen L; Selyutin O; Zeng Q; Dwyer MP; Nair AG; Shankar BB; Kim SH; Yang DY; Rosenblum SB; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Carr D; Curry S; McMonagle P; Bystol K; Lahser F; Ingravallo P; Chen S; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5354-5360. PubMed ID: 27680588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
    Tong L; Yu W; Coburn CA; Meinke PT; Nair AG; Dwyer MP; Chen L; Selyutin O; Rosenblum SB; Jiang Y; Fells J; Hu B; Zhong B; Soll RM; Liu R; Agrawal S; Xia E; Zhai Y; Kong R; Ingravallo P; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Oct; 26(20):5132-5137. PubMed ID: 27634194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of fluorobenzimidazole HCV NS5A inhibitors.
    Randolph JT; Flentge CA; Donner P; Rockway TW; Patel SV; Nelson L; Hutchinson DK; Mondal R; Mistry N; Reisch T; Dekhtyar T; Krishnan P; Pilot-Matias T; Stolarik DF; Beno DWA; Wagner R; Maring C; Kati WM
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5462-5467. PubMed ID: 27780635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
    Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Coburn CA; Nair AG; Wong M; Rosenblum SB; Zhou G; Dwyer MP; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Kim SH; Zeng Q; Selyutin O; Chen L; Masse F; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Lin M; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3414-20. PubMed ID: 27394665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
    Nakamura H; Fujioka S; Terui T; Okuda S; Kondo K; Tamatani Y; Akagi Y; Komoda Y; Kinoshita W; Ito S; Maeda K; Ukaji Y; Inaba T
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127361. PubMed ID: 32738974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity.
    Laporte MG; Jackson RW; Draper TL; Gaboury JA; Galie K; Herbertz T; Hussey AR; Rippin SR; Benetatos CA; Chunduru SK; Christensen JS; Coburn GA; Rizzo CJ; Rhodes G; O'Connell J; Howe AY; Mansour TS; Collett MS; Pevear DC; Young DC; Gao T; Tyrrell DL; Kneteman NM; Burns CJ; Condon SM
    ChemMedChem; 2008 Oct; 3(10):1508-15. PubMed ID: 18729128
    [No Abstract]   [Full Text] [Related]  

  • 10. Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Zhou G; Coburn CA; Zeng Q; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Ji T; Zan S; Chen L; Mazzola R; Kim JH; Sha D; Selyutin O; Rosenblum SB; Lavey B; Nair AG; Heon Kim S; Keertikar KM; Rokosz L; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4851-4856. PubMed ID: 27568086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
    Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
    Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
    Yu W; Hu B; Zhong B; Hao J; Lei Z; Agrawal S; Rokosz L; Liu R; Chen S; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2019 Mar; 29(5):700-706. PubMed ID: 30711390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer M; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1954-1957. PubMed ID: 29653894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs.
    Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5738-5742. PubMed ID: 25453811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.
    Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4508-4512. PubMed ID: 27506559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
    Tong L; Yu W; Chen L; Selyutin O; Dwyer MP; Nair AG; Mazzola R; Kim JH; Sha D; Yin J; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Xia E; Curry S; McMonagle P; Bystol K; Lahser F; Carr D; Rokosz L; Ingravallo P; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA
    J Med Chem; 2017 Jan; 60(1):290-306. PubMed ID: 27808515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.
    Belema M; Nguyen VN; St Laurent DR; Lopez OD; Qiu Y; Good AC; Nower PT; Valera L; O'Boyle DR; Sun JH; Liu M; Fridell RA; Lemm JA; Gao M; Knipe JO; Meanwell NA; Snyder LB
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4428-35. PubMed ID: 23803586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.